clinical trial · NCT06169319
A Study to Assess Collagenase Clostridium Histolyticum (CCH) in the Treatment of Plantar Fasciitis (PFA)
Plantar FasciitisCollagenase Clostridium Histolyticum (CCH)Placebo
brief summary
This study will assess the efficacy, safety, and tolerability of 2 different doses of collagenase clostridium histolyticum (CCH) (previously known as EN3835) compared to placebo.
started
Jan 3, 2024
primary completion
Sep 30, 2024
completion
Sep 30, 2024
last updated
Sep 30, 2025
official title
A Phase 2, Double-blind, Randomized, Placebo-controlled, Dose-ranging Study to Assess the Efficacy, Safety, and Tolerability of EN3835 vs Placebo in the Treatment of Plantar Fasciitis (PFA)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol